Percutaneous coronary intervention, commonly known as angioplasty or coronary angioplasty, is a therapeutic procedure used to treat the narrowed arteries of the heart. Close to a million angioplasties are performed in the U.S. each year. The Angioplasty CQI is designed to improve care for heart-disease patients who undergo angioplasty by reducing complications including kidney damage, the need for blood transfusions, and ultimately open-heart surgery. Participants also learn from one another by sharing best practices based on evidence-based medicine to improve quality and outcomes.
The initiative focuses on angioplasty procedures and collects data on approximately 25,000 artery-clearing angioplasties each year. It assesses complication rates such as kidney failure and heart attack as well as the need for emergency open heart surgery. Using the data, the initiative developed pocket-size cards and suggested guidelines to help physicians better manage patients at risk of serious complications by:
- Evaluating evidence-based disease management in patients undergoing angioplasty
- Identifying opportunities for quality improvement both locally and across the consortium
- Developing risk assessment models and tools
For more information, go to bmc2.org.
The Blue Cross Blue Shield of Michigan Cardiovascular Consortium-Percutaneous Coronary Intervention (BMC2-PCI) was the first Collaborative Quality Initiative. Results to date include:
- 5 percent reduction in contrast-induced nephropathy (2008-2014)
- 4 percent reduction in blood transfusions after angioplasty (2008-2014)
- 52 percent reduction in vascular complications (2008-2014)
- 20 percent increase in cardiac rehabilitation referral (2008-2014)
- In 2011, BMC2 PCI ventured into uncharted territory of physician review and compliance with nationally recognized appropriateness guidelines. In 2010, potentially inappropriate cases were an estimated 8.3 percent of all Michigan PCI cases; by 2013, this had dropped to 3 percent.